24/7 Market News Snapshot 22 October, 2024 – Akebia Therapeutics, Inc. (NASDAQ:AKBA)

October 22, 2024

DENVER, Colo., 22 October, 2024 (247marketnews.com) – (NASDAQ:AKBA) are discussed in this article.
Akebia Therapeutics, Inc. (AKBA) is experiencing a notable increase in its stock price, which opened at $1.39 and is currently trading at $1.545, reflecting a rise of approximately 12.77%. This uptick in value follows a previous closing price of $1.370 and is supported by a trading volume of 1.96 million shares, indicating heightened investor interest and a bullish sentiment. Market analysts suggest that this upward movement could signify a potential breakout from established resistance levels, presenting promising buying opportunities for traders. Sustained increases in volume will be crucial to confirm the legitimacy of this trend.

Adding to its momentum, Akebia has recently forged a significant partnership with a leading kidney care provider. This multi-year commercial agreement aims to enhance access to Vafseo® (vadadustat), a newly FDA-approved treatment designed to address anemia associated with chronic kidney disease (CKD) in dialysis patients. The collaboration allows physicians to prescribe Vafseo within an extensive network of over 200,000 patients across multiple dialysis centers, marking a substantial step in Akebia’s commercial strategy.

Vafseo is set to be available in January 2025, and this agreement underscores Akebia’s dedication to offering innovative solutions aimed at improving outcomes in kidney care. According to Nik Grund, Chief Commercial Officer of Akebia, this partnership will significantly expand healthcare providers’ ability to deliver this new treatment option, enhancing comprehensive care for dialysis patients.

With the recent FDA approval of Vafseo and a favorable reimbursement decision from the Center for Medicare & Medicaid Services effective January 2025, Akebia is poised to advance the treatment landscape for individuals affected by CKD, reaffirming its commitment to improving the quality of life for patients in need.

Related news for (AKBA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.